Apnimed, Inc.
Apnimed's sleep apnea pill AD109 has a February 28, 2027, FDA decision date. The drug showed a 44.1% reduction in breathing interruptions in trials, but the FDA questioned its clinical meaningfulness. Apnimed (APMD) relies on this single product, and its future hinges on FDA approval.
Apnimed, Inc. (APMD) President Dennis Patrick Molnar reported an internal reclassification on Aug. 3, 2026, converting each Class A share into one Common share under SEC Rules 16b-7 and 16b-3. The filing also lists new stock option grants, including 55,596 options at a $16.00 exercise price granted July 30, 2026, vesting monthly over 24 months.
Morningside Venture Investments Ltd purchased 312,500 shares of Apnimed, Inc. (APMD) at $16.00 ($5.00M total) on 2026-08-03.
Over the past 7 days, alphai's AI scored 1 news story mentioning APMD (Apnimed, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent APMD coverage spans ipo, insider activity and regulation.
In the last 30 days, APMD insiders filed 8 SEC Form 4 transactions — 2 purchases ($5.2M) and 6 sales. The most active reporter was Miller Lawrence G. with 5 filings.
The FDA timeline introduces uncertainty and potential upside if approval is granted, but also risk due to regulator concerns.
Routine insider equity administration plus a fresh option grant, with limited direct implications for near-term fundamentals.
This is a disclosed insider-style ownership increase by a large 10% holder, but it is not an executive transaction and lacks a 10b5-1 plan.
The IPO pricing and first trading details create an immediate supply and liquidity overhang, while the Phase 3 and NDA timeline provides a longer-dated catalyst path.
This is a disclosed insider open-market purchase, which can be read as modest bullish signaling but is not a fundamental catalyst by itself.
alphai scores every news story that mentions APMD with an AI model for sentiment and relevance, and aggregates insider trades from Apnimed, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Apnimed's sleep apnea pill AD109 has a February 28, 2027, FDA decision date. The drug showed a 44.1% reduction in breathing interruptions in trials, but the FDA questioned its clinical meaningfulness. Apnimed (APMD) relies on this single product, and its future hinges on FDA approval.
3 min readApnimed, Inc. (APMD) President Dennis Patrick Molnar reported an internal reclassification on Aug. 3, 2026, converting each Class A share into one Common share under SEC Rules 16b-7 and 16b-3. The filing also lists new stock option grants, including 55,596 options at a $16.00 exercise price granted July 30, 2026, vesting monthly over 24 months.
3 min readMorningside Venture Investments Ltd purchased 312,500 shares of Apnimed, Inc. (APMD) at $16.00 ($5.00M total) on 2026-08-03.
2 min readApnimed, Inc. (Nasdaq: APMD) priced and closed an upsized Nasdaq IPO raising $220.8M in gross proceeds. It sold 13.8M shares at $16.00 each, including 1.8M from the underwriters’ overallotment option. Shares began trading July 31, 2026. The company develops AD109 for obstructive sleep apnea, with two Phase 3 trials completed and an NDA PDUFA goal date of Feb. 28, 2027.
2 min readSEKHRI PAUL J purchased 12,500 shares of Apnimed, Inc. (APMD) at $16.00 ($0.20M total) on 2026-08-03.
2 min readApnimed raised $192M in its Nasdaq IPO, pricing 12M shares at $16 and debuting as APMD at $25, up 56% on the day. The company’s lead candidate Oxnimbi (formerly AD109) is under FDA review for obstructive sleep apnea. Apnimed submitted a new drug application in April; the FDA accepted it with a Feb. 28, 2027 decision date.
6 min readApnimed Inc. (Nasdaq: APMD) jumped 56% in its Nasdaq debut after pricing an enlarged $192M IPO. It sold 12M shares at $14-$16, closing at $25. The company reported $84.8M revenue and $67.7M net income for the quarter ended March 31. It is developing Oxnimbi for obstructive sleep apnea, with an FDA marketing request filed in April.
5 min readCAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- Apnimed, Inc. ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the pricing of its upsized initial public offering of 12,000,000 shares of its common stock at a price to the public of $16.00 per share.
2 min readS. Korea’s KOSPI surges over 16% as Samsung, SK Hynix rebound after Wall St rally Apnimed, Inc., a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, has priced its initial public offering of 12 million shares of common stock at $16.00 per share, according to a press release issued July 30, 2026. The company expects to raise $192 million in gross proceeds before deducting underwriting discounts, commissions, and offering expenses.
4 min readApnimed filed an S-1 for a US IPO of 10 million shares at $14 to $16, aiming to net about $134.6 million at the midpoint and about $155.5 million if underwriters exercise an option for 1.5 million more shares. The biotech’s lead drug Oxnimbi (AD109) targets obstructive sleep apnea; FDA accepted its NDA in July 2026 after two Phase III trials met primary endpoints.
4 min read
